Wassim Shaheen, MD
Cardiovascular Disease · Wichita, KSNPI 1780625558
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,657 of the $136,924 with a category attached, or 75.0%. 40 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 26.4% of the total. Reporting peaked in 2022 at $45,317 and has fallen 85.3% since, to $6,648 in 2025. Among cardiovascular disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,110 payments — averaging $123.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$36K
- AstraZeneca$33K
- Pfizer$25K
- Johnson & Johnson$23K
- Regeneron$10K
- Medtronic$3K
- plus $8K from 34 others
Across 94 payments — averaging $9385.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$763K
- Novartis$107K
- AstraZeneca$13K
What the payments were for
- Consulting fees$15,52511%
- Speaking & faculty fees$102,65775%
- Travel & lodging$2,1572%
- Food & beverage$16,28412%
- Education$3010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,924 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 3,943 | $3,718,405 |
| XareltoRivaroxaban | 933 | $963,580 |
| EntrestoSacubitril/Valsartan | 713 | $678,863 |
| FarxigaDapagliflozin Propanediol | 272 | $219,155 |
| CamzyosMavacamten | 24 | $203,830 |
| Repatha SureclickEvolocumab | 164 | $125,339 |
| BrilintaTicagrelor | 95 | $82,143 |
| MultaqDronedarone Hcl | 41 | $70,688 |
| JardianceEmpagliflozin | 57 | $66,915 |
| Praluent PenAlirocumab | 76 | $48,581 |
| Repatha SyringeEvolocumab | 44 | $36,020 |
| ClopidogrelClopidogrel Bisulfate | 2,917 | $19,823 |
| Atorvastatin Calcium | 2,813 | $15,480 |
| Midodrine Hcl | 251 | $15,184 |
| Metoprolol Succinate | 1,945 | $15,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24,505 | $3,718,4053,943 claims |
| Johnson & JohnsonXarelto | $22,902 | $963,580933 claims |
| NovartisEntresto | $1,513 | $678,863713 claims |
| AstraZenecaFarxiga, Brilinta | $33,253 | $301,299367 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $36,151 | $203,83024 claims |
| Sanofi-aventis U.S. LLCMultaq | $212 | $70,68841 claims |
| Boehringer IngelheimJardiance | $343 | $66,91557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
- Thomas AshcomWichita$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.